Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “DESIPRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 901 records · Page 50Linked to original sources
PubMed1996

Nitric oxide contributes to desipramine-induced hypotension in rats.

1. Anesthetized rats received the TCA desipramine (DMI) 60 mg kg-1 i.p. Administration of the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester-(L-NAME) 15 min after DMI reversed hypotension within 5 min (P < 0.05). In contrast to its beneficial effect on blood pressure, L-NAME worsened DMI-induced prolongation of the electrocardiographic QRS interval. Dexamethasone, an inhibitor of NOS induction, did not prevent DMI-induced hypotension. 2. To study the effect of L-NAME on survival, DMI was administered to anesthetized rats as a continuous i.v. infusion until death. Despite initially improving blood pressure, L-NAME decreased the mean survival time by 33% (P < 0.01) compared to control treatment. Administration of the nitric oxide (NO) donor nitroglycerine to rats during DMI infusion likewise decreased the mean survival time. 3. L-NAME partially reversed the hypotensive effect of nitroprusside in both anesthetized and awake rats. 4. These data suggest that NO production attributable to constitutive NOS (cNOS) activity aggravates the hypotension associated with DMI toxicity in the anesthetized rat, and contributes to the pathophysiology of this overdose. The shortened survival time produced by both increasing and decreasing NO production suggests that cNOS activity during DMI overdose is regulated and adaptive. Ongoing cNOS activity also contributed to nitroprusside-induced hypotension, and may represent a feature common to other drug-induced hypotensive states.

Animals↗
PubMed1990

Responses of growth hormone to desipramine in endogenous and non-endogenous depression.

Desipramine, a monoamine reuptake inhibitor, was used to stimulate release of growth hormone (GH) in 29 DSM-III major depressives and in 10 healthy controls. Eighteen of the depressives showed a blunted response. The GH-stimulation test was unable to distinguish endogenous from non-endogenous patients. The 13 dexamethasone non-suppressors were more likely to have a blunted GH response than the 14 suppressors. The results indicate that at least a subset of non-endogenous depressives have significant neuroendocrine abnormality.

Adult↗
PubMed1995

The effect of desipramine on basal and naloxone-stimulated cortisol secretion in humans: interaction of two drugs acting on noradrenergic control of adrenocorticotropin secretion.

Desipramine (DMI), a tricyclic antidepressant and norepinephrine (NE) reuptake blocker, is reported to induce ACTH and cortisol release acutely in humans, probably by facilitating central NE neurotransmission. Tricyclic antidepressant therapy, including DMI, normalizes the ACTH and cortisol hypersecretion that often accompanies depression. The mechanism of hypothalamic-pituitary-adrenal (HPA) axis inhibition by DMI in humans is unknown. In rats, DMI reduces the activity of the locus ceruleus, a major source of NE innervation of the hypothalamic paraventricular nucleus, the site of CRH neurons. Naloxone induces ACTH and cortisol release in humans through a noradrenergic-mediated mechanism and a probable consequent stimulation of hypothalamic CRH release. To study the interaction of these drugs on NE neurotransmission and, hence, HPA axis activity in humans, we administered DMI alone and with naloxone in a randomized, double blind, placebo-controlled protocol in eight healthy male volunteers. DMI (75 mg, orally) was given 180 min before naloxone (125 micrograms/kg BW, i.v.). Plasma ACTH and cortisol were measured at frequent intervals from 60 min before to 120 min after naloxone treatment. Plasma cortisol levels were 77% higher 180 min after DMI compared to those after placebo treatment (287 +/- 17 vs. 162 +/- 14 nmol/L; P = 0.000005). DMI reduced the naloxone-induced rise in cortisol (P = 0.02), but there was no change in the integrated cortisol response. The increase in basal plasma ACTH levels after DMI treatment did not reach statistical significance. DMI significantly increased systolic blood pressure and heart rate consistent with an effect on the noradrenergic control of the cardiovascular system. In summary, DMI increased basal cortisol levels consistent with facilitation of NE neurotransmission and, hence, hypothalamic CRH release. However, DMI had no enhancing effect on naloxone-induced cortisol release. This contrasts with the synergy observed when non-antidepressant agents that increase NE neurotransmission are given with naloxone to humans. DMI increases glucocorticoid feedback sensitivity in the rat HPA axis after several weeks through up-regulation of central corticosteroid receptors. However, this slowly developing effect is unlikely to occur during these acute studies. The effect of DMI on naloxone-induced cortisol release is consistent with an inhibitory effect on central noradrenergic control of ACTH release, perhaps at the locus ceruleus. This is the first human study to suggest an inhibitory effect of DMI on central noradrenergic control of ACTH release.

Adrenocorticotropic Hormone↗
PubMed2005

Different effects of desipramine on bufuralol 1''-hydroxylation by rat and human CYP2D enzymes.

Inhibitory effects of desipramine (DMI) on rat and human CYP2D enzymes were studied using bufuralol (BF) 1''-hydroxylation as an index. Inhibition was examined under the following two conditions: 1) DMI was co-incubated with BF and NADPH in the reaction mixture containing rat or human liver microsomes or yeast cell microsomes expressing rat CYP2D1, CYP2D2 or human CYP2D6 (co-incubation); 2) DMI was preincubated with NADPH and the same enzyme sources prior to adding the substrate (preincubation). When either rat liver microsomes or recombinant CYP2D2 was employed, the preincubation with DMI (0.3 microM) caused a greater inhibition of BF 1''-hydroxylation than the co-incubation did, whereas BF 1''-hydroxylation by rat CYP2D1 was not markedly affected under the same conditions. The inhibitory effect of DMI on BF 1''-hydroxylation by human liver microsomal fractions or recombinant CYP2D6 was much lower than that on the hydroxylation by rat liver microsomes or CYP2D2. Kinetic studies demonstrated that the inhibition-type changed from competitive for the co-incubation to noncompetitive for the preincubation in the case of CYP2D2, whereas the inhibition-type was competitive for both the co-incubation and the preincubation in the case of CYP2D6. Furthermore, the loss of activity of rat CYP2D2 under the preincubation conditions followed pseudo-first-order kinetics. Binding experiments employing the recombinant enzymes and [(3)H]-DMI revealed that CYP2D2 and CYP2D6 were the only prominent proteins to which considerable radioactive DMI metabolite(s) bound. These results indicate that rat CYP2D2 biotransforms DMI into reactive metabolite(s), which covalently bind to CYP2D2, resulting in inactivation of the enzyme. In contrast, human CYP2D6 may also biotransform DMI into some metabolite(s) that covalently bind to CYP2D6, but that do not inactivate the enzyme.

Adult↗
PubMed1983

Further studies on the suppressing effect of isoproterenol on the immobility-reducing action of desipramine in the forced swimming test.

The present study was undertaken to examine whether the suppressing effect of intracerebroventricular (i.c.v.) administration of isoproterenol (ISO) on the immobility-reducing action of desipramine (DMI) in the forced swimming test was mediated through the presynaptic noradrenaline (NA) neurons and presynaptic alpha 2-adrenoceptors in rat brain. As in the case of DMI, phenylephrine (i.c.v.) and yohimbine (i.p.) reduced the duration of immobility. The actions of DMI and yohimbine but not that of phenylephrine were diminished and potentiated by i.c.v. administration of ISO and atenolol, respectively. The suppressing effects of ISO were almost completely blocked by the pretreatment with atenolol. On the other hand, clonidine (s.c.) diminished the action of DMI as did ISO, although clonidine had no effect on the duration of immobility when given alone. The suppressing effect of clonidine was antagonized by the pretreatment with yohimbine at a dose which did not affect the duration of immobility, when given alone, nor influenced the action of DMI, whereas the effect of ISO was not affected by the same dose of yohimbine. These results suggest that the suppressing effect of ISO on the immobility-reducing action of DMI in the forced swimming test is mediated through the presynaptic NA neurons, and ISO acts through the presynaptic beta 1- but not alpha 2-adrenoceptors.

Animals↗
PubMedDate not supplied

Long-term desipramine or chlorpromazine treatment and rat brain N-methyl-D-aspartate receptor.

The effects of tricyclic antidepressants and antipsychotic drugs on the NMDA receptor in rat brain were investigated. Both types of drugs, in the micromolar concentration range and with Hill coefficients greater than unity, inhibited the binding of [3H]TCP to rat brain membranes. Tricyclic antidepressants containing secondary amine on the aliphatic side chain were more potent than the corresponding tertiary amine derivatives. Antipsychotic drugs containing large side chains were much less active than chlorpromazine. Neither tricyclic antidepressants nor antipsychotic drugs had an inhibitory effect on [3H]CPP binding to the glutamate site of the NMDA complex. Chronic administration of desipramine or chlorpromazine did not change the binding parameters of [3H]TCP to rat cerebral cortex membranes. It is possible that these psychoactive drugs bind to a site adjacent to the [3H]TCP binding site within the ionic channel of the NMDA receptor complex.

Animals↗
PubMed1988

Anhedonic ejaculation with desipramine.

Sexual dysfunction secondary to antidepressant drugs is an under-recognized clinical problem, and likely an important factor in noncompliance with treatment. We report two patients with anhedonic ejaculation (ejaculation without orgasm) associated with initiation of treatment with desipramine.

Attention↗
PubMed1996

N-sulphation of desipramine in the rat brain.

1. Amine N-sulphotransferase (NST) activity with desipramine (DMI) as substrate was assayed in vitro in various areas of the rat brain. Biosynthesis of 3'-phosphoadenosine-5'-phospho35sulphate (PAPS) from sodium 35sulphate and ATP was also measured by coupling it to the sulphation of minoxidil by minoxidil sulphotransferase (MST). 2. For the DMI-NST reaction, an apparent Km = 0.5 mM was obtained for DMI and two apparent Kms = 0.3 and 1.7 microM for PAPS, whereas in the PAPS-generating reactions, Km for sodium 35sulphate = 20 microM. 3. Both the enzyme activities were widely distributed in rat brain. The rate of NST activity was 2-3 orders of magnitude lower than that of PAPS generation. N-sulphoconjugation of DMI, which is proposed as a possible biotransformation pathway of DMI in the rat brain, could conceivably be supported adequately by the 'active sulphate' generated within the same areas of the brain.

Adenosine Triphosphate↗
PubMed1991

Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine.

Daily variations in the pharmacokinetics of imipramine (IMI) could contribute to circadian phase-dependent effects of the drug. Therefore, the chronopharmacokinetics of IMI and its metabolite, desipramine (DMI), were studied after single and chronic application. Male rats were synchronized to a 12:12 hour light:dark (L:D) regimen with lights on from 07:00 to 19:00 (dark, 19:00-07:00). In single-dose experiments rats were injected with IMI (10 mg/kg) i.p. or i.v. at 07:30 or 19:30 and groups of rats were killed 0-22 hours thereafter. After chronic application of IMI in drinking water (approximately 15 mg/kg/d) groups of rats were killed during the 14th day of treatment at 02:00, 08:00, 14:00, and 20:00, respectively. Brain and plasma concentrations of IMI and DMI were determined by reversed-phase high-performance liquid chromatography with ultraviolet detection. After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g). Also, the area under the curve (AUC) (0-22 hours) was about 1.6-fold greater in darkness than in light for IMI and DMI; half-lives were not circadian phase dependent. After i.v. injection of IMI, the AUC in brain was also about 30% greater in darkness than in light. After chronic application of IMI in drinking water, brain concentrations of IMI and DMI varied more than threefold within 24 hours. The data demonstrate that the pharmacokinetics of IMI and DMI are circadian phase dependent. It is assumed that circadian variations in drug distribution are more likely to contribute to the drug's chronopharmacokinetics than variations in the drug's metabolism. The 24-hour variations in the drug's concentrations after chronic IMI application in drinking water can be explained by the drinking behavior of the rats, which by itself is altered by IMI.

Analysis of Variance↗
PubMed1985

Agonist interactions with beta-adrenergic receptors following chronic administration of desipramine or the atypical antidepressants, iprindole and mianserin.

Desipramine (DMI), decreased the maximum number of beta-adrenergic receptors by approximately 10, 20, 30, and 20% in groups of rats treated i.p. with 5 mg/kg for 14 days or 10 mg/kg for 7, 14, or 21 days, respectively. In studies of agonist competition for beta-adrenergic receptors labelled with [125I]-CYP, chronic DMI administration caused a selective decrease in those receptors normally found in the high affinity conformation in proportion to the dose of DMI administered. No change was observed in either the number of receptors in the agonist low affinity conformation or in the affinity of any drug for the high or low affinity conformations of the receptors. Therefore, chronic DMI caused a selective decrease in the beta-adrenergic receptors linked to adenylate cyclase but did not appear to change other properties of the receptors that would be manifested as a change in their ability to interact with adrenergic agonists. Neither iprindole (15 mg/kg i.p., 14 days) nor mianserin (10 mg/kg i.p., 14 days) decreased the number of receptors, the proportions of agonist high or low affinity receptors, or the affinity of competitor drugs for these receptors, suggesting a different mechanism for the reported loss of adenylate cyclase activity following these drugs than the down-regulation of receptors observed with chronic DMI treatment.

Adrenergic beta-Agonists↗
PubMed1999

[The influence of L-triiodothyronine on the action of desipramine on beta and serotonin 2A receptor, monoamines in the rat brain].

The co-administration of thyroid hormone and antidepressants is often useful in the treatment of refractory depression. The aim of this study is to clarify the anti-depressive mechanisms of repeated co- administration of thyroid hormone (T3) and desipramine (DMI) in the rat brain. Forced swimming test, open-field test, monoamine contents, beta receptor, and serotonin (5HT)2A receptor were compared in four experimental groups (control, T3, DMI, DMI+T3). In the forced swimming test, the (DMI+T3) group showed a significantly decreased immobility time compared with that of the control group. The noradrenaline (NA) content in the prefrontal cortex was highest in the (DMI+T3) group. Although beta receptor was not altered in any brain region in the (DMI+T3) group, 5HT2A receptor was significantly decreased, and the dopamine (DA) turnover rate was significantly increased in the prefrontal cortex. This study suggests that the addition of T3 enhanced the action of DMI alone on the monoaminergic system in the prefrontal cortex.

Animals↗
PubMed1999

Desipramine and fluoxetine antagonized 5,7-dihydroxytryptamine-induced lesion on rat hippocampal and cortical neurons.

AIM: To assess the protective effect of desipramine (Des) and fluoxetine (Flu) on the neurons against the lesion induced by a selective serotonergic neurotoxin in vitro. METHODS: The 10-day cultured primary neurons of hippocampus and cortex of rat was exposed to 5,7-dihydroxytryptamine (5,7-DHT) to determine the optimal lesion concentration and duration. Before exposing to 5,7-DHT, Des and Flu was added to the medium for 30 min to observe the protective effects. RESULTS: The optimal concentration and duration for 5,7-DHT was 600 micromol.L-1 and 4 h, respectively. Both Des and Flu showed a protective effect in the dose range of 0.8 micromol.L-1 to 10 micromol.L-1 and 0.04 micromol.L-1 to 0.6 micromol.L-1, respectively, when the neurons were injured by 5,7-DHT 600 micromol.L-1 for 4 h. Flu showed a higher efficacy than Des. Both exhibited a more powerful protective effect on the hippocampal neuron than on the cortical neuron. CONCLUSION: The antidepressant effect of Des and Flu was attributed to their protective effect on the injured serotonergic neuron of the hippocampus and the cortex.

5,7-Dihydroxytryptamine↗
PubMed1975

Increased analgesia and alterations in distribution and metabolism of methadone by desipramine in the rat.

Treatment of rats with desipramine (DMI) 1 hour before the subcutaneous administration of methadone increased the intensity and prolonged the duration of methadone analgesia, as determined by the hot plate method. DMI significantly reduced the analgesic ED50 of methadone from a control value of 3.4 to 1.6 or 0.5 mg/kg in rats treated with 20 or 30 mg/kg of DMI, respectively. DMI treatment also significantly reduced the LD50 of methadone. DMI (20 mg/kg i.p.) was given 1 hour prior to administration of 14C-methadone (5 mg/kg s.c.) and the distribution of total 14C, unchanged methadone and methadone metabolites in various tissues was studied. DMI treatment greatly increased the brain uptake of 14C and the methadone brain/plasma concentration ratios for up to 3 hours. The concentrations of 14C and unchanged methadone were higher in kidneys and lower in lungs of DMI-treated rats as compared to controls. However, the ratios of unchanged methadone to its metabolites in kidneys and lungs were not changed significantly by DMI treatment. The level of unchanged methadone in liver was markedly elevated by DMI treatment at 45 and 90 minutes (190 and 183% of controls, respectively). The level of a water-soluble glucuronide metabolite of methadone was significantly decreased at 45-, 90- and 180-minute intervals (37, 36 and 54% of controls, respectively.) However, the total 14C in liver and the concentrations of two N-demethylated metabolites of methadone were not changed significantly. In vitro addition of DMI to liver microsomal incubations resulted in inhibition of the N-demethylation of methadone. It is suggested that DMI potentiated and prolonged methadone analgesia by increasing the brain concentration of methadone and by inhibiting metabolism of methadone in the liver.

Analgesia↗
PubMed2002

Desipramine antagonized corticosterone-induced apoptosis in cultured PC12 cells.

AIM: To study possible action mechanism of a tricyclic antidepressant, desipramine (DIM). METHODS: Cultured PC12 cells were exposed to corticosterone in the absence or presence of DIM for 5 d. Agarose gel electrophoresis, flow cytometry, and electron microscopy were used to detect the apoptosis of PC12 cells. RESULTS: Corticosterone 10 micromol/L treatment for 5 d elicited typical apoptotic biochemical and morphological changes including condensed chromatin shaped like crescent moon, nuclear fragmentation, and DNA degradation. The highest percentage of apoptotic cells accumulated to 28 % +/- 9 %. Agarose gel electrophoresis showed typical DNA ladders pattern. While in the presence of DIM 1 or 5 micromol/L, apoptosis percentage was markedly decreased with lightened DNA ladder and ultrastructure of the cells was improved. CONCLUSION: DIM could antagonize the apoptosis in PC12 cells induced by corticosterone, which may be one of the cellular mechanisms of its antidepressant effect.

Animals↗
PubMed2002

Caspase 3 gene expression and [Ca2+]i homeostasis underlying desipramine-induced C6 glioma cell apoptosis.

AIM: To study desipramine (Des)-induced apoptosis and regulation of caspase 3 gene expression and [Ca2+]i homeostasis in rat glioma C6 cells. METHODS: Apoptotic DNA breaks were quantified by propidium iodide (PI) incorporation using flow cytometry (FCM) and were detected by DNA agarose gel electrophoresis. Expression of apoptotic effector gene caspase 3 was assessed by reverse transcription polymerase chain reaction (RT-PCR). Single cell [Ca2+]i was measured using fluorescence indicator Fura-3/AM with confocal laser scanning microscopy. RESULTS: Des induced apoptotic DNA breaks in a concentration-dependent manner evidenced by hypodiploid peak on FCM histogram and the apoptotic cell percentage induced by Des 10, 20, and 40 micromol/L for 24 h was 5.2 %, 21.9 %, and 41.9 %, respectively. Apoptotic DNA breaks were further confirmed by a typical "DNA ladder" on agarose gel electrophoresis after exposure to Des 40 micromol/L for 24 h. Meanwhile, expression of caspase 3 gene was observed following Des 20 micromol/L treatment. Des 40 micromol/L resulted in an early sustained increase in [Ca2+]i over 28 min and the elevation magnitude was greatly decreased by removal of extracellular free [Ca2+]i with calcium-chelator egtazic acid, suggesting that Des elicited [Ca2+]i influx rather than intracellular calcium mobilization. CONCLUSION: Up-regulation of caspase 3 gene expression and disturbance of homeostasis in calcium signaling system might play pivotal roles in Des-induced apoptotic DNA breaks of C6 cells.

Animals↗
PubMed1992

Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: effects on hypotension and interaction with sodium bicarbonate.

The effect of drug-specific antibody Fab' fragment on desipramine (DMI) toxicity was studied in anesthetized rats to determine 1) whether DMI-induced hypotension can be reversed, and 2) whether the effect of this Fab' fragment can be enhanced by the concurrent administration of hypertonic NaHCO3. DMI (60 mg/kg) was administered i.p. to produce marked hypotension. Antitricyclic antidepressant (TCA) Fab' (molar Fab'/DMI ratio = 0.11) or control Fab' was administered 15 min later as a 10 min i.v. infusion. The mean arterial pressure was higher at the end of anti-TCA Fab' infusion than after control Fab' (58 +/- 8 vs. 17 +/- 7 mm Hg, P less than .001). In a second protocol, DMI (30 mg/kg) was administered to prolong QRS duration. Anti-TCA Fab' alone (molar Fab'/DMI ratio = 0.09) and NaHCO3 alone both reduced QRS prolongation compared to control treatment, and combined therapy was more effective than either one alone. In both protocols, anti-TCA Fab' markedly increased the total DMI concentration and the bound fraction of DMI in serum, but did not alter the unbound DMI concentration. In the low DMI dose protocol, anti-TCA Fab' also reduced the cardiac DMI concentration. Concurrent treatment with anti-TCA Fab' and NaHCO3 substantially increased urinary DMI and anti-TCA Fab' excretion compared to treatment with anti-TCA Fab' alone.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1992

ACTH accelerates the attenuation of alpha 2-adrenoceptors response in nucleus accumbens following chronic desipramine.

The inclusion of clonidine (CLO) induced a dose-dependent reduction of K(+)-evoked [3H] dopamine ([3H]DA) release in slices from rat nucleus accumbens. This inhibition was clearly attenuated in animals previously administered desipramine daily (DMI, 10 mg/kg i.p.) during 21 days, but not in rats submitted to a persistent treatment with DMI during 10 days. However, the coadministration of adrenocorticotrophic hormone (ACTH, 50 IU/kg s.c.) and DMI (10 mg/kg i.p.) for 10 days provoked a clear decrease in the inhibition produced by alpha 2-adrenoceptor stimulation, while ACTH alone had no effect. These results may indicate that ACTH accelerates the onset of DMI-induced adaptive changes on central alpha 2-adrenoceptor in the mesolimbic area.

Adrenocorticotropic Hormone↗
PubMed1992

Intravenous cocaine challenges during desipramine maintenance.

Intravenous challenges with placebo and cocaine doses ranging from 0.125 to 0.5 mg/kg were administered to five subjects using a within subjects design during placebo and active desipramine (DMI) maintenance at a fixed dose of 150 mg daily for at least 10 days. The "high" reported after cocaine infusion was not altered by DMI, but "desire for cocaine" after a single dose was attenuated. Together with the results of clinical trials of DMI for cocaine abuse, these laboratory results suggest that DMI may reduce cocaine craving both during and between cocaine binges. Physiologically, baseline heart rate was higher on DMI, but the incremental heart rate response to cocaine was attenuated.

Adult↗